163 related articles for article (PubMed ID: 34709739)
1. Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells.
Wang H; Sun J; Zhang B; Zhao D; Tong H; Wu H; Li X; Luo Y; Dong D; Yao Y; McDonald T; Stein AS; Al Malki MM; Pichiorri F; Carlesso N; Kuo YH; Marcucci G; Li L; Jin J
Clin Transl Med; 2021 Oct; 11(10):e610. PubMed ID: 34709739
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
3. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
4. TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS.
Monlish DA; Greenberg ZJ; Bhatt ST; Leonard KM; Romine MP; Dong Q; Bendesky L; Duncavage EJ; Magee JA; Schuettpelz LG
Exp Hematol; 2020 Aug; 88():42-55. PubMed ID: 32652111
[TBL] [Abstract][Full Text] [Related]
5. Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.
Gough SM; Chung YJ; Aplan PD
PLoS One; 2012; 7(5):e36876. PubMed ID: 22606303
[TBL] [Abstract][Full Text] [Related]
6. SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
Sun J; He X; Zhu Y; Ding Z; Dong H; Feng Y; Du J; Wang H; Wu X; Zhang L; Yu X; Lin A; McDonald T; Zhao D; Wu H; Hua WK; Zhang B; Feng L; Tohyama K; Bhatia R; Oberdoerffer P; Chung YJ; Aplan PD; Boultwood J; Pellagatti A; Khaled S; Kortylewski M; Pichiorri F; Kuo YH; Carlesso N; Marcucci G; Jin H; Li L
Cell Stem Cell; 2018 Sep; 23(3):355-369.e9. PubMed ID: 30146412
[TBL] [Abstract][Full Text] [Related]
7. Progressive genomic instability in the Nup98-HoxD13 model of MDS correlates with loss of the PIG-A gene product.
Byrne M; Bennett RL; Cheng X; May WS
Neoplasia; 2014 Aug; 16(8):627-33. PubMed ID: 25220590
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.
Slape CI; Saw J; Jowett JB; Aplan PD; Strasser A; Jane SM; Curtis DJ
Blood; 2012 Sep; 120(12):2475-83. PubMed ID: 22855610
[TBL] [Abstract][Full Text] [Related]
9. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
Slape C; Lin YW; Hartung H; Zhang Z; Wolff L; Aplan PD
J Natl Cancer Inst Monogr; 2008; (39):64-8. PubMed ID: 18648006
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.
Chung YJ; Robert C; Gough SM; Rassool FV; Aplan PD
Leuk Res; 2014 Jan; 38(1):95-102. PubMed ID: 23958061
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome.
Wen J; Huang Y; Li H; Zhang X; Cheng P; Deng D; Peng Z; Luo J; Zhao W; Lai Y; Liu Z
Int J Hematol; 2017 Jun; 105(6):777-783. PubMed ID: 28224273
[TBL] [Abstract][Full Text] [Related]
12. Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.
Xu H; Menendez S; Schlegelberger B; Bae N; Aplan PD; Göhring G; Deblasio TR; Nimer SD
Blood; 2012 Oct; 120(15):3089-97. PubMed ID: 22927245
[TBL] [Abstract][Full Text] [Related]
13. BOK promotes erythropoiesis in a mouse model of myelodysplastic syndrome.
Kang SH; Perales O; Michaud M; Katz SG
Ann Hematol; 2019 Sep; 98(9):2089-2096. PubMed ID: 31203423
[TBL] [Abstract][Full Text] [Related]
14. Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice.
Liu S; Joshi K; Zhang L; Li W; Mack R; Runde A; Hagen PA; Barton K; Breslin P; Ji HL; Kini AR; Wang Z; Zhang J
Cell Death Dis; 2024 Apr; 15(4):278. PubMed ID: 38637559
[TBL] [Abstract][Full Text] [Related]
15. MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.
Taggart J; Ho TC; Amin E; Xu H; Barlowe TS; Perez AR; Durham BH; Tivnan P; Okabe R; Chow A; Vu L; Park SM; Prieto C; Famulare C; Patel M; Lengner CJ; Verma A; Roboz G; Guzman M; Klimek VM; Abdel-Wahab O; Leslie C; Nimer SD; Kharas MG
Nat Commun; 2016 Feb; 7():10739. PubMed ID: 26898884
[TBL] [Abstract][Full Text] [Related]
16. PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.
Guirguis AA; Slape CI; Failla LM; Saw J; Tremblay CS; Powell DR; Rossello F; Wei A; Strasser A; Curtis DJ
Cell Death Differ; 2016 Jun; 23(6):1049-59. PubMed ID: 26742432
[TBL] [Abstract][Full Text] [Related]
17. Loss of p300 accelerates MDS-associated leukemogenesis.
Cheng G; Liu F; Asai T; Lai F; Man N; Xu H; Chen S; Greenblatt S; Hamard PJ; Ando K; Chen X; Wang L; Martinez C; Tadi M; Wang L; Xu M; Yang FC; Shiekhattar R; Nimer SD
Leukemia; 2017 Jun; 31(6):1382-1390. PubMed ID: 27881875
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of microRNA-144 inhibits proliferation and promotes the apoptosis of myelodysplastic syndrome cells through the activation of the AKAP12-dependent ERK1/2 signaling pathway.
Qian W; Jin F; Zhao Y; Chen Y; Ge L; Liu L; Yang M
Cell Signal; 2020 Apr; 68():109493. PubMed ID: 31809872
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome.
Choi Y; Hur EH; Moon JH; Goo BK; Choi DR; Lee JH
Korean J Intern Med; 2019 Mar; 34(2):390-400. PubMed ID: 29132200
[TBL] [Abstract][Full Text] [Related]
20. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
